IMGT

IMGT is a clinical-stage biotechnology company based in South Korea that specializes in integrating focused ultrasound (FUS) technology with nanotechnology to develop non-invasive drug delivery systems (DDS) for oncology. The company's lead product, IMD10, is a focused ultrasound device designed to enhance the penetration of chemotherapeutic agents into the dense tumor microenvironment of pancreatic cancer, recently receiving FDA Breakthrough Device Designation and Investigational Device Exemption (IDE) for a pivotal trial. In addition to medical devices, IMGT's pipeline includes nanoparticle-based chemoembolization (IMD20) and sonodynamic therapies aimed at treating liver and other solid tumors. Founded as a spin-off from Seoul National University Bundang Hospital, the company is publicly traded on the KONEX market and collaborates with partners like Samsung Medison to advance its ChemoSono Therapy platform.